Log In
BCIQ
Print this Print this
 

Mylan-Bosentan tablets

  Manage Alerts
Collapse Summary General Information
Company Mylan N.V.
DescriptionGeneric dual endothelin receptor antagonist
Molecular Target
Mechanism of ActionEndothelin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40,100.0M

$20,050.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/21/2015

$40,100.0M

$20,050.0M

0

Get a free BioCentury trial today